Pilot Study of Nasal Morphine-Chitosan for the Relief of Breakthrough Pain in Patients With Cancer
|
|
- Alexander Parks
- 5 years ago
- Views:
Transcription
1 598 Journal of Pain and Symptom Management Vol. 24 No. 6 December 2002 Clinical Note Pilot Study of Nasal Morphine-Chitosan for the Relief of Breakthrough Pain in Patients With Cancer Hilary Pavis, MA, MRCGP, Andrew Wilcock, DM, FRCP, Jane Edgecombe, MRCP, Diane Carr, RGN, Cathann Manderson, RGN, Ann Church, PhD, and Anthony Fisher, PhD Hayward House Macmillan Specialist Palliative Care Unit (H.P., A.W., J.E., D.C., C.M.), Nottingham City Hospital NHS Trust, and West Pharmaceutical Services (A.C., A.F.), Albert Einstein Center, Nottingham Science and Technology Park, Nottingham, United Kingdom Abstract Breakthrough pain in patients with cancer is common, often unpredictable, and can rapidly become severe. Treatment using the oral administration of opioids is not optimal due to the slow onset of pain relief. Nasal administration of analgesics potentially offers more rapid pain relief. This study investigates the tolerability and efficacy of a novel morphine-chitosan formulation. Twenty episodes of breakthrough pain were observed in 14 patients with cancer who received 5 80 mg of nasal morphine-chitosan. Nasal symptoms, sedation, giddiness, nausea, and other volunteered symptoms, along with pain scores (pain intensity and pain relief), were recorded at baseline and at regular intervals up to 4 hours after administration, together with an overall satisfaction rating. The formulation was acceptable to patients, generally well tolerated, and had an onset of pain relief 5 minutes after dosing. This formulation warrants further study. J Pain Symptom Manage 2002;24: U.S. Cancer Pain Relief Committee, Key Words Cancer, pain, breakthrough pain, morphine, nasal drugs Address reprint requests to: Andrew Wilcock, DM, FRCP, Hayward House Macmillan Specialist Palliative Care Unit, Nottingham City Hospital NHS Trust, Hucknall Road, Nottingham NG5 1PB, United Kingdom. Accepted for publication: January 19, Introduction Morphine, given regularly by mouth, is commonly recommended for the relief of cancer pain. 1 Breakthrough pain, a transitory exacerbation of pain in a patient who has mainly stable and adequately controlled pain, is generally treated with an additional dose of immediaterelease morphine, administered orally as a solution or tablet. Onset of pain relief may take minutes and peak analgesia one hour or more, in keeping with a mean (range) time to maximum plasma concentration of 1.1 ( ) hours. 2,3 Parenteral administration provides a more rapid onset of pain relief, but is not always an available, convenient, or preferred option. Thus, other non-oral routes of administration, such as transmucosal, nasal, or pulmonary, that may provide convenient and rapid pain relief are worth pursuing. 4 The nasal route of administration is potentially the most convenient alternative method for drug delivery. Nasal drug absorption is U.S. Cancer Pain Relief Committee, /02/$ see front matter Published by Elsevier, New York, New York PII S (02)
2 Vol. 24 No. 6 December 2002 Nasal Morphine-Chitosan for Breakthrough Pain 599 aided by a highly vascular epithelium, a large surface area and the avoidance of first pass metabolism. Morphine however, being hydrophilic, is poorly absorbed nasally. This problem may be overcome by combining morphine with chitosan, a bio-adhesive material that slows the mucociliary clearance of morphine, allowing more time for absorption. 5,6 In healthy volunteers, nasal morphine-chitosan is well tolerated, and has mean values for bioavailability, time to peak plasma concentration and elimination half-life of 56%, 15 minutes, and 3 hours, respectively. 7 In this pilot study, we have examined, for the first time, the tolerability and efficacy of a nasal morphine-chitosan solution in patients. Methods Subjects were inpatients at a specialist palliative care unit. All had cancer-related pain treated with regularly scheduled opioid administration and all experienced episodes of breakthrough pain, for which they used and found effective, additional doses of oral morphine. Episodes of breakthrough pain treated with nasal morphine-chitosan were of at least of moderate severity (i.e., 2 on the pain scale) and occurred more than one hour after any immediate-release morphine preparation. All regularly prescribed analgesics were continued. A maximum of two episodes was observed per patient. Patients were excluded if too frail or unwell to participate, psychological distress significantly contributed to their pain, or if their nasal passages were abnormal, congested, or occluded. Nasal morphine was administered by research staff in a standardized way using the same dose that the patient received orally for episodes of breakthrough pain. Two preparations of morphine-chitosan were supplied, 5 mg/0.1 ml and 20 mg/0.1 ml; this allowed morphine doses in the range of 5 80mg to be administered in 1 4 sprays from Pfeiffer single 0.1ml unit dosing devices (maximum of two sprays per nostril). Nasal symptoms (sore, itching or stinging nose, sore or stinging throat, dry or stuffy nose, runny nose, or taste disturbance), sedation, giddiness, nausea and other volunteered symptoms, along with pain scores (pain intensity and pain relief), were recorded at baseline and at regular intervals up to 4 hours after administration. Nasal symptoms, sedation, giddiness, nausea, and other symptoms were assessed on a scale of 0 4, where 0 represents none and 4 very severe. Pain intensity was recorded on a scale of 0 4, where 0 represents no pain and 4 very severe pain. Pain relief was assessed on a scale of 4 to 4, where 4 represents complete relief and 4 pain has become maximal. At the end of the study, patients were asked to provide an overall satisfaction rating of excellent, very good, good, fair, or poor. All patients gave written informed consent and the study was approved by Nottingham City Hospital Research Ethics Committee. Results Twenty episodes of pain were observed in 14 patients. There were 9 men and 5 women. The mean (range) age and World Health Organization performance status were 66 (44 79) years and 2.4 (1 3), respectively. In accordance with their usual dose of oral morphine for breakthrough pain, patients received one or two doses of 5 mg (3 patients), 10 mg (3 patients), 15 mg (2 patients), 20 mg (4 patients), 30 mg (1 patient) or 80 mg (1 patient) of nasal morphine. Overall Satisfaction Patients rated the 20 episodes with nasal morphine-chitosan as excellent (1), very good (6), good (11) and fair (2). Tolerability The majority of nasal symptoms were rated as 0 none or 1 slight, and were transient in nature (Table 1). Severe taste disturbance was reported in 4 episodes and appeared dose related. This occurred 5 minutes after dose administration in 3 patients, who described it as a bitter taste; in the fourth patient, it was reported prior to drug administration and remained unchanged throughout the study. The most frequent non-nasal adverse effect was sedation, reported at some point during 16 episodes. In 8 episodes, it appeared temporally related to the nasal morphine and, at its worst, patients rated it as very severe (1), moderate (2) or mild (5). During two episodes, sedation that was reported at baseline subsequently worsened following treatment. Baseline seda-
3 600 Pavis et al. Vol. 24 No. 6 December 2002 Table 1 Incidence (%) of Each Assessment Score and the Number of Episodes of Breakthrough Pain Recording that Score Variable No. of Episodes with a Incidence (%) of Score Score of: 0 none 1 slight 2 moderate 3 severe 4 very severe Sore/stinging nose 149 (83) 24 (13) 6 (3) 1 (1) 0 (0) Dry/stuffy nose 150 (83) 21 (12) 9 (5) 0 (0) 0 (0) Runny nose 158 (88) 19 (11) 3 (2) 0 (0) 0 (0) Sore/stinging throat 149 (83) 24 (13) 6 (3) 1 (1) 0 (0) Taste disturbance 121 (67) 36 (20) 12 (7) 11 (6) 0 (0) Nausea 158 (88) 18 (10) 4 (2) 0 (0) 0 (0) Sedation 101 (56) 47 (26) 26 (14) 5 (3) 1 (1) Giddiness 158 (88) 18 (10) 2 (1) 2 (1) 0 (0) Other symptoms a 4 (16) 11 (44) 6 (24) 1 (4) 3 (12) The total number of assessments for each variable was 180 (20 episodes 9 assessments). a Other symptoms (dry mouth/throat, light headedness, muscle aches) were recorded in 5 episodes (25 assessment scores in total). tion improved or stayed unchanged following treatment in two episodes each (Table 2). One patient reported a very severe dry mouth. This was present prior to administration, persisted over the first 15 minutes after dosing, and subsequently improved to slight over the duration of the study. Efficacy Improvements in pain intensity and relief were reported at 5 minutes and reached a maximum after 45 minutes, at which time pain intensity was rated as slight and pain relief as eased moderately. In 9 episodes, patients received a dose of a regularly prescribed analgesic 1 4 hours after nasal morphine-chitosan. Mean pain intensity and relief scores for the first hour following administration of nasal morphine are therefore presented, as no additional regular analgesic was administered during this period (Figure 1). Discussion Breakthrough pain in patients with cancer is common, often unpredictable and can be severe. 8,9 Morphine given orally, although commonly used, is not optimal due to the slow onset of pain relief. Parenteral administration provides a more rapid onset of pain relief, but is not always available or convenient. Exploration of other routes of analgesic administration for the treatment of breakthrough pain has seen the development of the oral transmucosal fentanyl citrate lozenge, which provides more rapid onset pain relief than oral morphine. 10,11 This formulation has some limitations; the effective dose for a patient is difficult to predict and requires dose titration, it is unsuitable in approximately 25% of patients, and is expensive. We, like others, have explored the delivery of strong opioids nasally The nose has a large surface area due to microvilli on the epithelial surface and is highly vascularized. These Table 2 Assessment Scores of Sedation Following Nasal Morphine-Chitosan Episode number Time (min) none, 1 slight, 2 moderate, 3 severe, 4 very severe.
4 Vol. 24 No. 6 December 2002 Nasal Morphine-Chitosan for Breakthrough Pain 601 Fig. 1. Mean pain intensity and relief after nasal morphine-chitosan (n 20). characteristics aid drug absorption. The venous blood drains from the nose directly into the systemic circulation, avoiding hepatic first-pass metabolism. Drugs with a small molecular weight that are predominantly lipophilic are most rapidly absorbed. 15 Hydrophilic drugs can be removed from the nasal cavity by the mucociliary clearance mechanism before sufficient absorption can occur. Chitosan is a linear cationic polysaccharide, produced from chitin extracted from crustacean shells, and acts as a bio-adhesive material by binding strongly to negatively charged biological surfaces such as mucus membranes. The clearance from the nasal cavity of formulations containing chitosan is thus delayed, increasing the time available for drug absorption. 6 The addition of chitosan to morphine increases its nasal bio-availability from about 10% to 54%, with a time to maximum concentration of 15 minutes. 7 Chitosan is not absorbed, is bio-compatible, non-toxic, and lacks irritant or allergic effects. 16 The administration of nasal morphine-chitosan appears acceptable to patients, with the majority rating their overall satisfaction as good or very good. The formulation was well tolerated nasally, with reported symptoms generally mild and transient except for a severe bitter taste, most likely the result of clearance of some morphine into the oropharynx. The doses that were studied would provide the dose of breakthrough analgesia required by most patients. The most frequent non-nasal adverse effect was sedation, reported in 16 episodes (Table 2). In 8 episodes, sedation appeared temporally related to the administration of nasal morphine-chitosan. It is difficult to explore this fully, in an uncontrolled study, however, particularly in the presence of other factors that may contribute to sedation. A controlled and blinded comparison with oral morphine would be useful in this regard. The incidence of sedation could suggest that the use of a nasal to oral dose ratio of 1:1 is excessive. The mean (range) oral bio-availability of morphine is reported as 38% (15 64%). 2 In the elderly, due to reduced hepatic metabolism, bio-availability is likely to be at the upper end of the range, approximating that seen after nasal administration, and formed the rationale for the 1:1 ratio. 7,17 Dose-titration or relative potency studies of oral and nasal morphine are needed to explore this further. Nasal morphine-chitosan appears to have a rapid onset of effect. Reports of pain relief and of reduced pain intensity were seen after only 5 minutes, progressively improving until reaching a maximum after 45 minutes. Confirmation is required in controlled studies that include oral morphine and oral transmucosal fentanyl citrate as comparators. In conclusion, this pilot study suggests that nasal morphine-chitosan formulation is acceptable to patients, is generally well tolerated, and may lead to rapid onset of pain relief. This formulation has the potential to allow morphine, a commonly used opioid for the relief of cancer pain, to be given in a way that is more rapidly effective and more convenient than the oral route. This could be of particular benefit to patients at home, and for those unable to swallow or who are vomiting. We believe this formulation warrants further examination in controlled studies. Acknowledgment The authors would like to thank West Pharmaceutical Services for the manufacture, release, and supply of the nasal morphine-chitosan formulation and for contributing towards the costs of this study. References 1. Hanks GWC, De Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Brit J Cancer 2001;84:
5 602 Pavis et al. Vol. 24 No. 6 December Twycross RG, Wilcock A, Charlesworth S, Dickman A. Palliative Care Formulary (2nd Ed.). Oxon: Radcliffe Medical Press, Collins SL, Faura CC, Moore A, McQuay HJ. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998;16: Wilcock A. New approaches to pain management. Prog in Pall Care 2001;9: Soane RJ, Frier M, Perkins AC, et al. Evaluation of the clearance characteristics of bio-adhesive systems in humans. Int J Pharm 1999;178: Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11: West Pharmaceutical Services, data on file. 8. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81: Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: survey of hospice patients on admission. Palliat Med 2001;15: Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized double- blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90: Christie JM, Simmonds M, Patt R et al. Dosetitration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16: Wilson JA, Kendall JM, Cornelius P. Intranasal diamorphine for paediatric analgesia: assessment of safety and efficacy. J Accid Emerg Med 1997;14: Striebel HW, Wessel A, Rieger A, Boerger N. Intranasal fentanyl for breakthrough cancer pain or incident pain. Br J Anaesth 1993;70:A210, Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med 2000;14: Illum L, Fisher AN. Intranasal delivery of peptides and proteins. In: Adjei AL, Gupta PK, eds. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker Inc, 1997: Dodane V, Vilivalam V. Pharmaceutical applications of chitosan. Pharm Sci Tech Today 1998;1: Baillie SP, Bateman DN, Coates PE, Woodhouse KW. Age and the pharmacokinetics of morphine. Age Ageing 1989;18:
Dose titration of sublingual fentanyl, in relation to transdermal fentanyl dosing in cancer patients
74 Dose titration of sublingual fentanyl, in relation to transdermal fentanyl dosing in cancer patients Amaniti E MD, PhD, Zaralidou A MD, Maidatsi P MD, PhD, Mitos G MD, Thoma G MD, Vasilakos D MD, PhD.
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Fentanyl Pectin Nasal Spray Provides Clinically Meaningful Pain Relief and a More Rapid Onset of Analgesia compared with Immediate-release Morphine Sulphate in Breakthrough
More informationNew Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain
New Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain Abstral is to be reviewed for use within: Primary Care Secondary
More informationGUIDELINES FOR THE MANAGEMENT OF CANCER-RELATED BREAKTHROUGH PAIN
GUIDELINES FOR THE MANAGEMENT OF CANCER-RELATED BREAKTHROUGH PAIN 1. GENERAL PRINCIPLES Breakthrough cancer pain (BTcP) is thought to occur frequently particularly in in patients with advanced disease.
More informationNOVIDADES NO TRATAMENTO COM OPIOIDES. Novelties in therapeutic with opioids. V Congresso National de Cuidados Palliativos Marco 2010, Lisboa
NOVIDADES NO TRATAMENTO COM OPIOIDES Novelties in therapeutic with opioids V Congresso National de Cuidados Palliativos 11 12 Marco 2010, Lisboa Friedemann Nauck Department Palliative Medicine Center Anesthesiology,
More informationTHE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT
1 THE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT Jaegtvolden 4-5 June 2012 14. 12. 2012 2 1 3 WHO ANALGESIC LADDER (1996) NSAID +/- Adjuvant STEP II OPIODS Opids for mild to moderate
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Topic: fentanyl-containing medications: - Actiq, fentanyl citrate oral transmucosal lozenges - Abstral fentanyl sublingual tablets - Fentora, fentanyl buccal tablet - fentanyl
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More information358 Journal of Pain and Symptom Management Vol. 41 No. 2 February 2011
358 Journal of Pain and Symptom Management Vol. 41 No. 2 February 2011 Original Article Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with
More informationScottish Medicines Consortium
Scottish Medicines Consortium fentanyl 50 micrograms / dose, 100 micrograms/dose, 200 micrograms / dose nasal spray (Instanyl ) No. (579/09) Nycomed UK Ltd 09 October 2009 The Scottish Medicines Consortium
More informationSprays for pain management as an alternative to injection and other routes of administration
Prescription Division Sprays for pain management as an alternative to injection and other routes of administration A scientific roundtable hosted by Aptar Pharma Prescription Division Delivering solutions,
More informationSafety and Effectiveness of Intravenous Morphine for Episodic (Breakthrough) Pain Using a Fixed Ratio with the Oral Daily Morphine Dose
352 Journal of Pain and Symptom Management Vol. 27 No. 4 April 2004 Original Article Safety and Effectiveness of Intravenous Morphine for Episodic (Breakthrough) Pain Using a Fixed Ratio with the Oral
More informationSafety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine
Vol. 32 No. 2 August 2006 Journal of Pain and Symptom Management 175 Original Article Safety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine
More informationBreakthrough Cancer Pain: Ten Commandments
VALUE IN HEALTH 19 (2016) 531 536 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval ISSUE HIGHLIGHTS Decision-Maker Commentary Breakthrough Cancer Pain: Ten Commandments
More informationCHILDREN S SERVICES. Trust Medicines Policy and Procedures Paediatric Pain Assessment Chart
CHILDREN S SERVICES POLICY AND PROCEDURE FOR THE ADMINISTRATION OF INTRANASAL DIAMORPHINE VIA SYRINGE OR ATOMIZER FOR PAEDIATRIC ANALGESIA IN PAEDIATRIC A&E See also: Trust Medicines Policy and Procedures
More informationOpioid Conversion Ratios - Guide to Practice 2010
Opioid Conversion Ratios - Guide to Practice 2010 Released December 2010. 2010. The EMR PCC grants permission to reproduce parts of this publication for clinical and educational use only, provided that
More informationClinically Important Changes in Acute Pain Outcome Measures: A Validation Study
406 Journal of Pain and Symptom Management Vol. 25 No. 5 May 2003 Original Article Clinically Important Changes in Acute Pain Outcome Measures: A Validation Study John T. Farrar, MD, MSCE, Jesse A. Berlin,
More informationWhat is cancer breakthrough pain?
Chapter 2 What is cancer breakthrough pain? Definitions The original definition of cancer breakthrough pain (cbtp), given by Portenoy and Hagen [1], is the template upon which the majority of subsequent
More informationOral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology
REVIEW Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology Kyriaki Mystakidou 1 Eleni Tsilika 1 Marinos Tsiatas 2 Lambros Vlahos 3 1 Pain Relief and
More informationOpioid Conversion Guidelines
Opioid Conversion Guidelines March 2015 Gippsland Region Palliative Care Consortium Clinical Practice Group Title Keywords Ratified Opioid, Conversion, Drug, Therapy, Palliative, Guideline, Palliative,
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Opioids in the Medically Ill: Principles of Administration Russell K. Portenoy, MD Chief Medical Officer MJHS Hospice and Palliative Care Director MJHS Institute for Innovation
More informationBreakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights
Breakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights Steven Wong, MD Assistant Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, UCLA David Geffen School of Medicine
More informationCLINICAL POLICY FOR THE USE OF INTRANASAL DIAMORPHINE FOR ANALGESIA IN CHILDREN ATTENDING THE PAEDIATRIC EMERGENCY DEPARTMENT, SASH
CLINICAL POLICY FOR THE USE OF INTRANASAL DIAMORPHINE FOR ANALGESIA IN CHILDREN ATTENDING THE PAEDIATRIC EMERGENCY DEPARTMENT, SASH Background Adequate analgesia is a vital aspect of early management of
More informationThe use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing
Critical Reviews in Oncology/Hematology 80 (2011) 460 465 The use of rapid onset opioids for breakthrough cancer pain: The challenge of its dosing Sebastiano Mercadante a,b, a Anesthesia and Intensive
More informationCare of the Dying: Is Pain Control Compromised or Enhanced by Continuation of the Fentanyl Transdermal Patch in the Dying Phase?
398 Journal of Pain and Symptom Management Vol. 24 No. 4 October 2002 Original Article Care of the Dying: Is Pain Control Compromised or Enhanced by Continuation of the Fentanyl Transdermal Patch in the
More informationThe Pain Pen for Breakthrough Cancer Pain: A Promising Treatment
Vol. 29 No. 2 February 2005 Journal of Pain and Symptom Management 213 Clinical Note The Pain Pen for Breakthrough Cancer Pain: A Promising Treatment Roelien H. Enting, MD, Carlo Mucchiano, MD, Wendy H.
More informationLondon New Drugs Group APC/DTC Briefing Document
Page 1 London New Drugs Group APC/DTC Briefing Document Fentanyl preparations for breakthrough cancer pain Contents Summary 1 Issues for consideration 3 Background 3 Doses 4 Other treatments 4 Patients
More informationNATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND
Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report
Suffolk PCT Drug & Therapeutics Committee New Medicine Report This drug has been reviewed because it is a product that may be prescribed in primary care. Medicine Fentanyl citrate oral and intranasal preparations
More informationGUIDELINES FOR STRONG OPIOID SUBSTITUITION IN PALLIATIVE CARE
GUIDELINES FOR STRONG OPIOID SUBSTITUITION IN PALLIATIVE CARE 30.1 GENERAL PRINCIPLES Morphine is the strong opioid of choice in palliative care. 1, 2 Options for opioid substitution include oxycodone,
More informationSyringe driver in Palliative Care
Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24
More informationWhat else is new (symptoms)? DR ANDREW DAVIES
What else is new (symptoms)? DR ANDREW DAVIES Introduction Outline Rapid onset opioids for episodic breathlessness Alcohol for anorexia (white wine) Rapid onset opioids for episodic breathlessness Episodic
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationClinical Trial Results with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S25 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationLong Term Care Formulary HCD - 08
1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally
More informationFinal Appraisal Report. Fentanyl (Instanyl ) Nycomed UK Ltd. Advice No: 0710 April Recommendation of AWMSG
Final Appraisal Report Fentanyl (Instanyl ) Nycomed UK Ltd Advice No: 0710 April 2010 Recommendation of AWMSG Fentanyl intranasal spray (Instanyl ) is recommended as an option for use within NHS Wales
More informationGG&C Chronic Non Malignant Pain Opioid Prescribing Guideline
GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline Background Persistent pain is common, affecting around five million people in the UK. For many sufferers, pain can be frustrating and disabling,
More informationHowida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University
Pharmacy Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University Pharmacy Pharmacy Pharmaceutics The science of dosage form design. Pharmacy 1. 2. 3. Dosage forms Information Resources Use of
More informationAn Italian survey on the attitudes in treating breakthrough cancer pain in hospice
Support Care Cancer (2011) 19:979 983 DOI 10.1007/s00520-010-0919-5 ORIGINAL ARTICLE An Italian survey on the attitudes in treating breakthrough cancer pain in hospice Sebastiano Mercadante & Patrizia
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationBreakthrough Pain in Oncology: A Longitudinal Study
Vol. 40 No. 2 August 2010 Journal of Pain and Symptom Management 183 Original Article Breakthrough Pain in Oncology: A Longitudinal Study Sebastiano Mercadante, MD, Vittoria Zagonel, MD, Enrico Breda,
More informationOpioid Pearls and Acute Pain Management
Opioid Pearls and Acute Pain Management Jeanie Youngwerth, MD University of Colorado Denver Assistant Professor of Medicine, Hospitalist Associate Director, Colorado Palliative Medicine Fellowship Program
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More informationNebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study
Vol. 29 No. 6 June 2005 Journal of Pain and Symptom Management 613 Clinical Note Nebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study Eduardo Bruera, MD, Raul Sala,
More informationCurrent and Emerging Pharmacotherapies of Breakthrough Pain in Cancer
Clinical Medicine Reviews in Oncology R e v i e w Current and Emerging Pharmacotherapies of Breakthrough Pain in Cancer Jeffrey B. Rubins Hospice and Palliative Care, Minneapolis Veterans Affairs Medical
More informationThe U&lity of Opioids for Breakthrough Cancer Pain
The U&lity of Opioids for Breakthrough Cancer Pain John Zeppetella MD(Res), FRCGP, FRCP Medical Director, St Clare Hospice john.zeppetella@stclarehospice.org.uk Josep Porta Sales MD, PhD InsFtut Català
More informationIntranasal Delivery of Morphine
0022-3565/02/3011-391 400$7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 301, No. 1 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 4411/973874
More informationAlternative Routes to Oral Opioid Administration in Palliative Care: A Review and Clinical Summary
Alternative Routes to Oral Opioid Administration in Palliative Care: A Review and Clinical Summary Matthew G. Kestenbaum, MD, Agustin O. Vilches, RPh, Stephanie Messersmith, MS, Stephen R. Connor, PhD,
More informationAnalgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-
Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the
More informationORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA
ORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: Fentanyl by oral transmucosal and nasal delivery Actiq (fentanyl citrate) lozenge on a handle 200,
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
More informationOpioid Escalation in Patients with Cancer Pain: The Effect of Age
Vol. 32 No. 5 November 2006 Journal of Pain and Symptom Management 413 Original Article Opioid Escalation in Patients with Cancer Pain: The Effect of Age Sebastiano Mercadante, MD, Patrizia Ferrera, MD,
More informationThe Use of Transdermal Opioids in Palliative Care. G. Whyte, P.Powell, C. Littlewood, A. Coackley, G. Leng External Reviewer/Expert : S.
The Use of Transdermal Opioids in Palliative Care G. Whyte, P.Powell, C. Littlewood, A. Coackley, G. Leng External Reviewer/Expert : S. Simpson 1 Introduction Dr Graham Whyte Literature Review Dr Paula
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationPharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist What is the difference between pharmacokinetics and pharmacodynamics? Definitions Pharmacokinetics = what the body does
More informationManagement of cancer pain
DOI 10.1007/s11739-010-0448-8 SYMPOSIUM: MANAGING OF COMPLICATIONS IN PATIENTS WITH CANCER Management of cancer pain Sebastiano Mercadante Ó SIMI 2010 Abstract In the last decades, studies validating the
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationSpecialist Palliative Care Audit and Guidelines Group (SPAGG)
Specialist Palliative Care Audit and Guidelines Group (SPAGG) Clinical Guideline for the Prescribing and Administration of Furosemide via continuous subcutaneous infusion (CSCI) for Heart Failure Patients
More informationTransmucosal Immediate Release Fentanyl (TIRF) Prior Authorization, (Through Generic), and Quantity Limit Program Summary
Transmucosal Immediate Release Fentanyl (TIRF) Prior Authorization, (Through Generic), and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-5 Drug Indication Dosage Abstral (fentanyl sublingual
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationThe Treatment of Breakthrough Pain
Blackwell Publishing IncMalden, USAPMEPain Medicine1526-2375American Academy of Pain Medicine? 20078S1813Original ArticleTreatment of Breakthrough PainMcCarberg PAIN MEDICINE Volume 8 Number S1 2007 The
More informationNicotine Replacement Therapy, Zyban and Champix. Name of presentation
Nicotine Replacement Therapy, Zyban and Champix Nicotine Replacement Therapy (NRT) - Rationale for use Nicotine is highly addictive and causes unpleasant withdrawal symptoms which often undermine a quit
More informationTopic Brief BREAKTHROUGH CANCER PAIN
Topic Brief BREAKTHROUGH CANCER PAIN Pain is one of the most common, yet underreported, misunderstood and feared symptoms of having cancer. Most people with cancer will experience pain at some point during
More informationGUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE
GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE GENERAL PRINCIPLES Methadone may be used as a strong opioid alternative when severe cancer-related pain responds poorly to other opioids, or
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationRoutes of drug administration
Routes of drug administration Definition:- A route of administration in pharmacy is the path by which a drug is taken into the body. Classification:- The various routes of administrations are classified
More informationDistribution The in vitro protein binding for Mometasone furoate was reported to be 98% to 99% in concentra on range of 5 to 500 ng/ml.
NOSATREX Composition Mometasone Furoate 0.05% w/w Spray Action Mechanism of Action Mometasone Nasal Spray 50 mcg is a cor costeroid demonstra ng potent an -inflammatory properties. The precise mechanism
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Transmucosal Fentanyl Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 1018 Table of Contents Coverage Policy... 1 General
More informationThe Bioavailability of Morphine Applied Topically to Cutaneous Ulcers
434 Journal of Pain and Symptom Management Vol. 27 No. 5 May 2004 Original Article The Bioavailability of Morphine Applied Topically to Cutaneous Ulcers Maria D.C. Ribeiro, MRCP, Simon P. Joel, PhD, and
More informationFentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl
RESEARCH ARTICLE Pain Management For reprint orders, please contact: reprints@futuremedicine.com Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl David
More informationCell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p.
Cell Membranes, Epithelial Barriers and Drug Absorption p. 1 Introduction p. 2 The Plasma Membrane p. 2 The phospholipid bilayer p. 3 Dynamic behaviour of membranes p. 4 Modulation of membrane fluidity
More informationSam H Ahmedzai Academic Unit of Supportive Care Department of Oncology The University of Sheffield & Sheffield Teaching Hospitals NHS Foundation
Sam H Ahmedzai Academic Unit of Supportive Care Department of Oncology The University of Sheffield & Sheffield Teaching Hospitals NHS Foundation Trust Overview Which drugs? How much? How to give? Adverse
More informationCurrent controversies in the assessment and management of breakthrough cancer pain
Review issue Andrew Davies Consultant in Palliative Medicine, Royal Surrey County Hospital Current controversies in the assessment and management of breakthrough cancer pain Abstract Breakthrough cancer
More informationQ&A: Opioid Prescribing for Chronic Non-Malignant Pain
NHS Hastings and Rother Clinical Commissioning Group Chair Dr David Warden Chief Officer Amanda Philpott NHS Eastbourne, Hailsham and Seaford Clinical Commissioning Group Chair Dr Martin Writer Chief Officer
More informationOpioid Conversions Mixture of Science and Art
Opioid Conversions Mixture of Science and Art Matthew J. Pingree, MD Assistant Professor Division of Pain Medicine Physical Medicine and Rehabilitation and Anesthesiology Mayo Clinic, Rochester Pingree.Matthew@Mayo.edu
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.CPA.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder
More informationOpioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.
Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient
More information1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER 1.1 GENERAL PRINCIPLES There are many causes of agitation in palliative care patients, which makes recommendations for treatment difficult.
More informationIntravenous Fentanyl for Cancer Pain: A Fast Titration Protocol for the Emergency Room
876 Journal of Pain and Symptom Management Vol. 26 No. 3 September 2003 Clinical Note Intravenous Fentanyl for Cancer Pain: A Fast Titration Protocol for the Emergency Room Luiz Guilherme L. Soares, MD,
More informationPalliative Care Impact Survey
September 2018 Contents Introduction...3 Headlines...3 Approach...4 Findings...4 Which guideline are used...4 How and where the guidelines are used...6 Alternative sources of information...7 Use of the
More informationEducation Program for Prescribers and Pharmacists
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)
More informationIntranasal Medications
Intranasal Medications Mike Harlos MD, CCFP, FCFP Professor and Section Head, Palliative Medicine, University of Manitoba Medical Director, WRHA Adult and Pediatric Palliative Care The presenter has no
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More informationSingle- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers
Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers Pamela P. Palmer, MD, PhD AcelRx Pharmaceuticals, Inc. October 20, 2009 1 Sufentanil: A Superior Opioid Approved
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationTime to Pain Relief After Immediate-Release Morphine in Episodic Pain The TIME Study
ORIGINAL RESEARCH ARTICLE Clin Drug Investig 21; 3 Suppl. 2: 49-55 1173-2563/1/2-49/$49.95/ ª 21 Adis Data Information BV. All rights reserved. Time to Pain Relief After Immediate-Release Morphine in Episodic
More informationGuidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)
Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth) Policy Number : DC020 Issue Date: October 2014 Review date: October 2016 Policy Owner: Head Community Services Monitor:
More informationSyringe Drivers. Back to top
Page 1 of 8 Syringe Drivers Introduction Indications for use Advantages Method Siting syringe driver Boost facility Transfer to hospital/hospice syringe driver drugs Drug compatibility P.r.n medication
More informationGUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE
GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE 41.1 GENERAL PRINCIPLES The ICD 10 diagnostic criteria for dependency syndrome are listed in Table 41.1 below.
More informationNew Methods for Analgesia Delivery
New Methods for Analgesia Delivery Guy Ludbrook MBBS PhD FANZCA Royal Adelaide Hospital and University of Adelaide South Australia Anesthesiology is on the verge of a major evolution that will involve
More informationSmoking and Nicotine Replacement Therapy (NRT) Lec:5
Smoking and Nicotine Replacement Therapy (NRT) Lec:5 Tobacco use remains the single largest preventable cause of mortality. Cigarette smoke is a complex mixture of an estimated 4800 compounds. Approximately
More informationThe Mid Yorkshire Macmillan Specialist Palliative Care Team
The Mid Yorkshire Macmillan Specialist Palliative Care Team Morphine and Strong Opioid information leaflet Information for patients/carers The mere mention of Morphine can be enough to conjure up all sorts
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.HNMC.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationImmediate release fentanyl (DROP-List)
Bulletin 132 April 2016 Community Interest Company Immediate release fentanyl (DROP-List) This is one of a number of bulletins providing further information on medicines contained in the PrescQIPP DROP-List
More informationThis program is supported by an educational grant from Meda Valeant Pharma Canada Inc.
This program is supported by an educational grant from Meda Valeant Pharma Canada Inc. Introduction This CME program was developed to enhance the awareness of physicians on the assessment and management
More informationThe last days of life in hospital and at home
The last days of life in hospital and at home Beaumont Multi-disciplinary Palliative Care Study Day 28/9/2017 Dr Sarah McLean Consultant in Palliative Medicine St Francis Hospice Beaumont Hospital Overview
More informationDetermination of bioavailability
Pharmaceutics 2 Bioavailability Bioavailability is the rate and extent to which an administered drug reaches the systemic circulation. For example, if 100 mg of a drug is administered orally and 70 mg
More information